Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs
| العنوان: | Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs |
|---|---|
| المؤلفون: | Majed M. Khraishi, Valencia P. Remple, Samuel Silverberg, Jacqueline C. Stewart, Brandusa Florica, Louis Bessette |
| المصدر: | The Journal of Rheumatology. 49:454-464 |
| بيانات النشر: | The Journal of Rheumatology, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Adult, Biological Products, Canada, Epidemiologic Studies, Treatment Outcome, Rheumatology, Antirheumatic Agents, Arthritis, Psoriatic, Immunology, Adalimumab, Humans, Pain, Immunology and Allergy |
| الوصف: | ObjectiveCOMPLETE-PsA was an observational study of biologic-naïve Canadian adults with active psoriatic arthritis (PsA) treated with adalimumab (ADA) or a nonbiologic disease-modifying antirheumatic drug (nbDMARD) regimen, after inadequate response/intolerance to a current nbDMARD treatment regimen. The aim of this analysis was to assess the 12-month effectiveness of ADA vs nbDMARDs.MethodsPatients enrolled between March 2012 and November 2017 were included. The following clinical variables and patient-reported outcomes were collected/calculated per routine care: Disease Activity Index for Psoriatic Arthritis in 28 joints (DAPSA28), Disease Activity Score in 28 joints (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein, physician global assessment (PGA), patient global assessment (PtGA), pain, Health Assessment Questionnaire–Disability Index (HAQ-DI), 12-item Short Form Health Survey, enthesitis, dactylitis, body surface area (BSA), and time to achieving American College of Rheumatology (ACR) 50, ACR70, and modified minimal disease activity (mMDA).ResultsTwo hundred and seventy-seven ADA-treated and 148 nbDMARD-treated patients were included. At baseline, ADA-treated patients were less likely to be employed, had longer morning stiffness, higher DAPSA28, DAS28, PGA, PtGA, pain, and HAQ-DI, and lower prevalence of dactylitis (allP< 0.05). ADA-treated patients showed lower baseline-adjusted DAPSA28 (16.5 vs 26.6), DAS28 (2.8 vs 3.9), PGA (25.3 vs 37.1), and ESR (10.4 vs 15.0 mm/h) after 3 months compared to nbDMARD-treated patients, with observed improvements maintained to month 12. Time to achievement of ACR50, ACR70, and mMDA was significantly shorter (P< 0.001) among ADA-treated patients, with the likelihood of having dactylitis (odds ratio [OR] 0.4, 95% CI 0.2–0.6) and BSA< 3% (OR 2.7, 95% CI 1.5–5.0) significantly lower and higher, respectively. Switching to another biologic was less likely in ADA-treated vs nbDMARD-treated patients (hazard ratio 0.3, 95% CI 0.2–0.5).ConclusionIn a real-world Canadian population of patients with PsA, ADA was more effective than nbDMARDs at reducing disease activity and the severity of skin involvement, and demonstrated higher retention. [ClinicalTrials.gov:NCT01559038] |
| تدمد: | 1499-2752 0315-162X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72413cf5fa35c246d3d7a98e4cff9a8d https://doi.org/10.3899/jrheum.200609 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....72413cf5fa35c246d3d7a98e4cff9a8d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14992752 0315162X |
|---|